NCT06620003View on ClinicalTrials.gov

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 14, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Marburg Virus Disease
Interventions
BIOLOGICAL

cAd3-Marburg Vaccine

The recombinant chimpanzee adenovirus Type 3-vectored Marburg vaccine, (cAd3-Marburg Vaccine) is composed of a cAd3 vector that expresses Marburg wild type glycoprotein (WT GP) from the Angola strain.

BIOLOGICAL

Placebo

0.9% NaCl solution for injection.

Trial Locations (7)

32934

Optimal Research; LLC, Melbourne

35802

Optimal Research; LLC, Huntsville

60602

Synexus Clinical Research US, Inc., Chicago

61614

Optimal Research; LLC, Peoria

75234

Synexus Clinical Research US; Inc., Dallas

78229

Synexus Clinical Research US, Inc., San Antonio

85020

Synexus Clinical Research US, Inc., Phoenix

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Albert B. Sabin Vaccine Institute

OTHER